SCHEMBL4348405

SCHEMBL4348405

CCNc1cc(Cl)cc(COc2c(Br)cc(C(=O)NCC(=O)O)cc2Br)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
THRB P10828 4/20 0.37
THRA P10827 3/20 0.37
GPR139 Q6DWJ6 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 2/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
HPGD P15428 1/20 0.34
DDR1 Q08345 4/20 0.33
PDE5A O76074 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
FABP4 P15090 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922926 0.90 SMN1; SMN2 (0.38) SMN1; SMN2MAPTRAB9AL3MBTL1THRB
SCHEMBL4353638 0.88 GPR139 (0.39) SMN1; SMN2MAPTRAB9AL3MBTL1THRB
SCHEMBL4355678 0.87 THRA (0.43) SMN1; SMN2MAPTRAB9AL3MBTL1THRB
SCHEMBL5110782 0.86 CA1 (0.37) SMN1; SMN2MAPTRAB9AL3MBTL1THRB
SCHEMBL5717812 0.83 DDR1 (0.32) SMN1; SMN2MAPTRAB9AL3MBTL1DDR1
SCHEMBL5717815 0.83 DDR1 (0.32) SMN1; SMN2MAPTRAB9AL3MBTL1DDR1
SCHEMBL4361512 0.82 PDE4A (0.37) SMN1; SMN2MAPTRAB9AL3MBTL1THRB
SCHEMBL4927472 0.82 SMN1; SMN2 (0.36) SMN1; SMN2MAPTRAB9AL3MBTL1THRB
SCHEMBL4922427 0.81 SMN1; SMN2 (0.36) SMN1; SMN2MAPTRAB9AL3MBTL1THRB
SCHEMBL5717904 0.81 DDR1 (0.31) DDR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009080835-A1 THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING KARO BIO AB (SE) 2009-07-02 WO disclosed
US-20080221210-A1 Thyroid Receptor Agonists KARO BIO AB (SE) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221210-A1 Thyroid Receptor Agonists TSHR, TRHR, THRA SMN1; SMN2 4282/4885MAPT 4142/4885RAB9A 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.